



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 7035

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

08 December 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to treatment of neurology patients.

You asked:

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

- a. *Aubagio (teriflunomide)*
- b. *Avonex (interferon beta-1a)*
- c. *Betaferon (interferon beta-1b)*
- d. *Brabio (glatiramer acetate)*
- e. *Copaxone (glatiramer acetate)*
- f. *Extavia (beta interferon-1b)*
- g. *Fampyra (fampridine)*
- h. *Gilenya (fingolimod)*
- i. *Lemtrada (alemtuzumab)*
- j. *Mavenclad (cladribine)*
- k. *Mayzent (siponimod)*
- l. *Ocrevus (ocrelizumab)*
- m. *Plegridy (peginterferon beta-1a)*
- n. *Rebif (beta interferon-1a)*
- o. *Tecfidera (dimethyl fumarate)*
- p. *Tysabri (natalizumab)*
- q. *Zeposia (ozanimod)*

Q2. How many patients have been treated with the following drugs in the past 4 months:

- a. *Aimovig (erenumab) - any disease*
- b. *Ajovy (fremanezumab) - any disease*
- c. *Emgality (galcanezumab) - any disease*
- d. *Botulinum Toxin (i.e. Botox, Dysport, Xeomin) –for migraine ONLY*

Q3. Does the trust either commission or fund Botulinum Toxin treatment and/or anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine (Y/N)?

Q4. How many patients have been treated in the past 4 months for the following conditions:

- a. Chronic migraine (15+ headache days per month)
- b. Episodic migraine (4-14 headache days per month)
- c. Relapsing remitting multiple sclerosis (RRMS)
- d. Primary progressive multiple sclerosis (PPMS)
- e. Secondary progressive multiple sclerosis (SPMS)

Trust response:

Please note: The way the Pharmacy data is recorded has changed. Data is now collected by finance quarter:

Q1 April, May, June

Q2 July, August, September

Q3 October, November, December

Q4 January, February, March

The following data is for April 2021 to September 2021

1.

Plegridy	35
DIMETHYL FUMARATE	108
COPAXONE	47
Betaferon	5
avonex	27

Any drugs not included in this list are either not dispensed/supplied or on the trust formulary.

2.

Botulinum Toxin Migraine (disorder) 18

3. Pharmacy unable to answer.

4. a/b.

Headache is the commonest reason for referral to general neurology and many patients will be migraineurs of differing forms. In order to find the information requested the Trust will need to manually check the medical records of every patient. The Trust has estimated that it will cost more than the appropriate limit to consider this part of your request. The appropriate limit is specified in regulations and represents the estimated cost of one person spending 3 ½ working days in determining whether the Trust holds the information, locating, retrieving and extracting the information. Under Section 12 of the Freedom of Information Act 2000 the Trust is not obliged to comply with this part of your request and we will not be processing this part of your request further.

c/d/e. The primary and secondary progressive MS patients who are on treatment are included within the numbers provided in response to Q1.